J&J Will Boost OTC Marketing Once Reliable Production Returns
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson CEO Alex Gorsky says he expects 75% of OTC products previously recalled to be back on the market in 2013, and the firm will begin prioritizing marketing efforts once a consistent supply of products is restored. The McNeil Fort Washington facility will remain offline another year.
You may also be interested in...
For J&J OTC Sales, Tylenol Arthritis Label Approval Could Bring Relief Closer
FDA’s approval positions J&J/McNeil to return Tylenol 8HR Arthritis to the market with new packaging to interest consumers while also sustaining their connection with the iconic brand. The latest label design for the product features different color schemes and text fonts than the most recent previous changes.
For J&J OTC Sales, Tylenol Arthritis Label Approval Could Bring Relief Closer
FDA’s approval positions J&J/McNeil to return Tylenol 8HR Arthritis to the market with new packaging to interest consumers while also sustaining their connection with the iconic brand. The latest label design for the product features different color schemes and text fonts than the most recent previous changes.
In Brief: First Response, DXM bills, J&J OTCs, Nu Skin record
First Response Gold makes earliest detection claim; Virginia passes DXM age restriction; J&J “confident in communicating” on OTCs; Nu Skin reports record quarter, year; and more In Brief.